Ingo Mellinghoff

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Signal transduction inhibitors and antiangiogenic therapies for malignant glioma
    Ingo K Mellinghoff
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
    Glia 59:1205-12. 2011
  2. pmc Will kinase inhibitors make it as glioblastoma drugs?
    Ingo K Mellinghoff
    Department and Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Curr Top Microbiol Immunol 355:135-69. 2012
  3. pmc Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?
    Ingo Mellinghoff
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    PLoS Med 4:1620-2. 2007
  4. ncbi request reprint Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2
    Marc R J Carlson
    Department of Human Genetics, University of California at Los Angeles and David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California 90095 1271, USA
    Clin Cancer Res 13:2592-8. 2007
  5. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013

Collaborators

Detail Information

Publications5

  1. doi request reprint Signal transduction inhibitors and antiangiogenic therapies for malignant glioma
    Ingo K Mellinghoff
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
    Glia 59:1205-12. 2011
    ..2011 Wiley-Liss, Inc...
  2. pmc Will kinase inhibitors make it as glioblastoma drugs?
    Ingo K Mellinghoff
    Department and Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Curr Top Microbiol Immunol 355:135-69. 2012
    ....
  3. pmc Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?
    Ingo Mellinghoff
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    PLoS Med 4:1620-2. 2007
  4. ncbi request reprint Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2
    Marc R J Carlson
    Department of Human Genetics, University of California at Los Angeles and David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California 90095 1271, USA
    Clin Cancer Res 13:2592-8. 2007
    ..VEGF inhibition reduces edema and tumor burden in some patients with malignant glioma, whereas others show no response. The role of VEGF expression in edema production and the relationship to survival is not well understood...
  5. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
    ..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)...